DermAll nanomedicine for allergen-specific immunotherapy

• Published in: Nanomedicine 2013-11, Vol.9 (8), p.1245-1254
• Main Authors: Garaczi, Edina, MD, PhD, Szabó, Kornélia, PhD, Francziszti, László, MSc, Csiszovszki, Zsolt, PhD, Lőrincz, Orsolya, MSc, Tőke, Enikő R., PhD, Molnár, Levente, MSc, Bitai, Tamás, MSc, Jánossy, Tamás, MD, PhD, Bata-Csörgő, Zsuzsanna, MD, DSc, Kemény, Lajos, MD, DSc, Lisziewicz, Julianna, PhD
• Format: Article
• Language: English
• Subjects: Administration, Topical; Allergens - genetics; Allergens - immunology; Animals; Cytokines - immunology; DermaVir; Epicutaneous Immunotherapy; Female; Immunization; Immunoglobulin E - blood; Immunoglobulin E - immunology; Internal Medicine; Langerhans Cells - immunology; Langerhans Cells - metabolism; Mice; Mice, Inbred BALB C; Nanomedicine; Ovalbumin - genetics; Ovalbumin - immunology; Plasmids - administration & dosage; Plasmids - genetics; Plasmids - immunology; Plasmids - therapeutic use; Rhinitis, Allergic; Rhinitis, Allergic, Perennial - blood; Rhinitis, Allergic, Perennial - immunology; Rhinitis, Allergic, Perennial - prevention & control; Th2 Cells - immunology; Vaccines, DNA - administration & dosage; Vaccines, DNA - genetics; Vaccines, DNA - immunology; Vaccines, DNA - therapeutic use
• ISSN: 1549-9634; 1549-9642
• DOI: 10.1016/j.nano.2013.05.011

Abstract Allergen-specific immunotherapy (ASIT) the only disease-modifying treatment for IgE-mediated allergies is characterized with long treatment duration and high risk of side effects. We investigated the safety, immunogenicity and efficacy of a novel ASIT, called DermAll, in an experimental allergic rhinitis model. We designed and characterized DermAll-OVA, a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin (OVA) as model allergen. DermAll-OVA was administered topically with DermaPrep device to target Langerhans cells. To detect the clinical efficacy of DermAll ASIT we quantified the nasal symptoms and characterized the immunomodulatory activity of DermAll ASIT by measuring cytokine secretion after OVA-stimulation of splenocytes and antibodies from the sera. In allergic mice DermAll ASIT was as safe as Placebo, balanced the allergen-induced pathogenic TH 2-polarized immune responses, and decreased the clinical symptoms by 52% [32%, 70%] compared to Placebo. These studies suggest that DermAll ASIT is safe and should significantly improve the immunopathology and symptoms of allergic diseases. From the Clinical Editor A novel allergen-specific immunotherapy for IgE-mediated allergies is presented in this paper, using an experimental allergic rhinitis model and a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin as model allergen. Over 50% reduction of symptoms was found as the immune system's balance was favorably altered toward more TH 2-polarized immune responses.